362057University of Gondar, College of Medicine and Health Sciences, Gondar, Ethiopia.
J Evid Based Integr Med. 2021 Jan-Dec;26:2515690X211003727. doi: 10.1177/2515690X211003727.
Currently, the coronavirus disease 2019 (COVID-19) is a big challenge to the healthcare systems in the world. Several researchers in the world have immediately carried out clinical investigations for the discovery of vaccines and drugs. Different studies have shown that antiviral measures including small bioactive compounds targeting multifaceted molecular communications take in COVID-19 infection. The drug development archived in this review emphasizes mainly on drugs that are effective for the Management of MERS-CoV, SARS-CoV, and other RNA viruses. The investigation of therapeutic agents for COVID-19 includes anti-inflammatory agents, antibodies, and nucleic acid-based treatments targeting virus gene expression as well as different sorts of vaccines. Numerous patents revealed techniques of these biologics with the potential for treating and preventing coronavirus infections, which may apply to COVID-19. Phase 3 clinical trials such as Sputnik V, AZD1222, mRNA-1273, BNT162b2, Ad5-nCoV, Anti-COVID antibodies, Kevzara; Actemra, Jakafi; Baricitinib, and some others were undergoing in the race for Covid-19 treatment. However, there's still a lack of a review on vaccines and drugs for COVID-19 management. Therefore, this review summarizes different studies that are ongoing in the race for Covid-19 protection and treatment.
目前,2019 年冠状病毒病(COVID-19)对世界各国的医疗保健系统构成了重大挑战。世界上的几位研究人员立即开展了临床研究,以发现疫苗和药物。不同的研究表明,针对 COVID-19 感染的抗病毒措施包括针对多方面分子通讯的小分子生物活性化合物。本综述中药物开发主要侧重于对中东呼吸综合征冠状病毒(MERS-CoV)、严重急性呼吸综合征冠状病毒(SARS-CoV)和其他 RNA 病毒有效的药物。针对 COVID-19 的治疗剂的研究包括抗炎药、抗体以及针对病毒基因表达的核酸治疗以及各种疫苗。大量专利揭示了这些生物制剂的技术,这些技术具有治疗和预防冠状病毒感染的潜力,可能适用于 COVID-19。Sputnik V、AZD1222、mRNA-1273、BNT162b2、Ad5-nCoV、抗 COVID 抗体、Kevzara;Actemra、Jakafi;巴瑞替尼和其他一些药物正在进行 3 期临床试验,以治疗 COVID-19。然而,对于 COVID-19 管理的疫苗和药物,仍缺乏综述。因此,本综述总结了正在进行的针对 COVID-19 保护和治疗的不同研究。